Centrexion Therapeutics to Present at the Jefferies 2017 Global Healthcare Conference

BOSTON--()--Centrexion Therapeutics, a company focused on advancing the treatment of chronic pain with one of the largest exclusively pain-focused pipelines of non-opioid therapies in active development, today announced that Jeffrey B. Kindler, chief executive officer, will provide a company overview at the Jefferies 2017 Global Healthcare Conference on Thursday, June 8, 2017 at 9:30 a.m. ET. The conference is taking place June 6-9, 2017 at the Grand Hyatt hotel in New York City.

About Centrexion Therapeutics

Centrexion Therapeutics, Corp. is focused on advancing the treatment of chronic moderate to severe pain with one of the largest exclusively pain-focused pipelines of non-opioid, non-addictive therapies in active development. Centrexion Therapeutics recognizes the needs of over a quarter of a billion people living with chronic pain worldwide, and aims to develop new, safer and more effective therapies that overcome the limitations and challenges associated with current pain treatments. Founded by world-renowned leaders in drug development and well-funded by key investors, Centrexion Therapeutics is building a pain treatment powerhouse to address the substantial and growing global chronic pain epidemic. Centrexion Therapeutics has recently relocated from Baltimore, Md. to Boston, Mass.

For more information about Centrexion, visit http://www.centrexion.com.

Contacts

Pure Communications, Inc.
Julie Normart, 415-946-1087
jnormart@purecommunications.com

Contacts

Pure Communications, Inc.
Julie Normart, 415-946-1087
jnormart@purecommunications.com